

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



39187

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 31/00		A2	(11) International Publication Number: WO 00/50024 (43) International Publication Date: 31 August 2000 (31.08.00)
<p>(21) International Application Number: PCT/US00/05282</p> <p>(22) International Filing Date: 25 February 2000 (25.02.00)</p> <p>(30) Priority Data: 60/121,754 26 February 1999 (26.02.99) US</p> <p>(71) Applicant (<i>for all designated States except US</i>): INSPIRE PHARMACEUTICALS, INC. [US/US]; Suite 470, 4222 Emperor Boulevard, Durham, NC 27703 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (<i>for US only</i>): YERXA, Benjamin, R. [US/US]; 1330 Hathaway Road, Raleigh, NC 22608 (US). RIDEOUT, Janet, L. [US/US]; 3101 Morningside Drive, Raleigh, NC 27607-3010 (US). JONES, Arthur, C. [US/US]; 5 Winnabow Court, Durham, NC (US).</p> <p>(74) Agent: HALLUIN, Albert, P.; Howrey Simon Arnold & White, LLP, 1299 Pennsylvania Avenue, N.W., Washington, DC 20004 (US).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>	
<p>(54) Title: METHOD OF PROMOTING MUCOSAL HYDRATION WITH CERTAIN URIDINE, ADENINE AND CYTIDINE DIPHOSPHATES AND ANALOGS THEREOF</p> <p>(57) Abstract</p> <p>A method and preparation for the stimulation of mucosal hydration in a subject in need of such treatment is disclosed. The method comprises administering to the mucosal surfaces of the subject a purinergic receptor agonist such as uridine 5'-diphosphate (UDP), dinucleotides, cytidine 5'-diphosphate (CDP), adenosine 5'-diphosphate (ADP), or their therapeutically useful analogs and derivatives, in an amount effective to stimulate mucin secretion. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include: topical administration via a liquid, gel, cream, or as part of a contact lens or selective release membrane; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, intra-operative instillation or suppository form. A method for facilitating the expectoration of sputum for the purpose of detecting cellular abnormalities indicative of lung disease is also disclosed.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

METHOD OF PROMOTING MUCOSAL HYDRATION WITH CERTAIN URIDINE, ADENINE AND CYTIDINE DIPHOSPHATES AND ANALOGS THEREOF

5

INTRODUCTION

This application claims priority to U.S. Provisional Application No.

10 60/121,754, filed February 26, 1999.

Technical Field

This invention relates to a method of regulating secretions in and around the mucous membranes of a mammal by administering purinergic receptor agonists such as certain uridine, adenine, or cytidine diphosphates as well as other nucleoside phosphate compounds.

Background of the Invention

There are many situations where it is therapeutically desirable to increase the amount of hydration on mucosal surfaces of the body. Mucus membranes are hydrated surface epithelial tissues that line cavities exposed to the outside environment. These mucosal surfaces of the body must stay hydrated with the proper mixtures of water, salt, mucin and other proteins in order to defend the body from the outside world and remain comfortable. The mucus membranes play a major role in fighting off infections and keeping the exposed organs clean and healthy. Mucus membranes are found on the surface of the eye, vagina, sinonasal cavities and mouth (oropharyngeal). Impaired hydration of these mucus membranes leads to medical conditions such as: dry eye, vaginal dryness, rhinosinusitis, dry mouth, corneal injury, and others.

30 Dry eye disease is the general term for indications in which the mucous membranes surrounding the eye are not properly hydrated due to an imbalance of salt, water and mucus in the precorneal tear film. Dry eye is characterized by a decrease in tear production or an increase in tear film evaporation, together with the ocular

surface disease that results. Approximately 38 million Americans are affected with some type of dry eye disorder. Among the indications that are referred to by the general term "dry eye disease" are: keratoconjunctivitis sicca (KCS), age-related dry eye, Stevens-Johnson syndrome, Sjogren's syndrome, ocular cicatrical pemphigoid, 5 blepharitis, corneal injury, infection, Riley-Day syndrome, congenital alacrima, nutritional disorders or deficiencies (including vitamin deficiencies), pharmacologic side effects, eye stress and glandular and tissue destruction, environmental exposure to smog, smoke, excessively dry air, airborne particulates, autoimmune and other immunodeficient disorders, and comatose patients rendered unable to blink. The 10 present invention may also be useful as a wash or irrigation solution in conscious individuals, during surgery or to maintain comatose patients or those who cannot blink due to neuromuscular blockade or loss of the eyelids.

Currently, the pharmaceutical treatment of dry eye disease is mostly limited to administration of artificial tears (saline solution) to temporarily rehydrate the eyes. 15 However, relief is short-lived and frequent dosing is necessary. In addition, artificial tears often have contra-indications and incompatibility with soft contact lenses (M. Lemp, *Cornea* 9(1):S48-550 (1990)). The use of phosphodiesterase inhibitors, such as 3-isobutyl-1-methylxanthine (IBMX) to stimulate tear secretion is disclosed in U.S. Patent No. 4,753,945. The effectiveness of these phosphodiesterase inhibitors is 20 currently being investigated (J. Gilbard, et al., *Arch. Ophthal.* 112:1614-16 (1994) and 109:672-76 (1991); idem, *Inv. Ophthal. Vis. Sci.* 31:1381-88 (1990)). Stimulation of tear secretion by topical application of melanocyte stimulating hormones is described in U.S. Patent No. 4,868,154.

Vaginal dryness is a very common problem which brings physical and 25 emotional distress to many women (E. Key, *Nurs. Stand.* 5:24-27 (1991)). It most commonly manifests itself during sexual intercourse, which causes dyspareunia and can eventually lead to apareunia. Although it is traditionally considered to be a condition which affects postmenopausal women, it can occur during the

premenopausal and perimenopausal years. The use of oral contraceptives may also cause a reduction in vaginal moisture in some women (W. Reginald, et al., *Br. J. Obstet. Gynaecol.* 96:1148-1152 (1989)). Postpartum vaginal dryness, independent of or as a result of lactation, can be a significant complaint (P. Wisniewski, et al., *Am. J. Obstet. Gynecol.* 165:1249-1254 (1991)).

Women undergoing chemotherapy or radiotherapy for malignant diseases such as leukemia often experience vaginal dryness as a result of treatment (M. Cust, et al., *Br. Med. J.* 299:1494-1497 (1989)).

Many disease states, such as systemic sclerosis and other systemic autoimmune disorders (S. Bhaduria, et al., *Am. J. Obstet. Gynecol.* 172:580-587 (1995)), Ehlers-

10 Danlos syndrome (Y. Sorokin, et al., *J. Reprod. Med.* 39:281-284 (1994)), diabetes mellitus (L. Sreebny, et al., *Diabetes Care* 15:900-904 (1992)), and Sjögren's syndrome (D. Marchesoni, et al., *Eur. J. Obstet. Gynecol. Reprod. Biol.* 63:49-53 (1995)) have decreased vaginal hydration and lubrication problems as significant disease-associated symptoms.

15 Current therapies for increasing vaginal moisture are: lubricating agents such

as lubricating creams or jellies, topical estrogen creams, and HRT (hormone replacement therapy). Lubricating jellies provide short-lived and temporary relief, as these are aqueous preparations containing no pharmacologically active agent. Topical estrogen creams, if used on a regular basis, may be absorbed into the systemic

20 circulation. This can cause endometrial stimulation and can lead to endometrial hyperplasia and carcinoma (M. Whitehead, et al., *N. Eng. J. Med.* 305:1599-1605 (1981)). HRT is effective at relieving symptoms of vaginal atrophy and hence vaginal dryness but has several contraindications and unwanted risks and side effects.

Another disease state characterized by improper hydration of mucus secretions

25 is acute and chronic sinusitis, or rhinosinusitis as it is currently referred to by otolaryngologists. Rhinosinusitis is a disease of the paranasal sinuses typically associated with retained, thick mucus secretions. It is this country's most common health-care complaint, affecting an estimated 31 million people (A. Moss and V.

Parsons, National Center for Health Statistics, 1986: 66-7, DHHS Publication No. (PHS) 86-1588 (1985)).

5 Dry mouth is a condition in which the mucus membranes of the oropharyngeal cavity becomes dehydrated, leading to discomfort, difficulty swallowing and bad breath. Among the conditions generally referred to as "dry mouth" are, but not limited to: Sjogren's syndrome, chemotherapy and post radiation treatment, and pharmacologic side effects.

10 Thus, as a result of the ineffectiveness and risks of current therapies, medical researchers have sought to develop alternatives for the treatment of dehydrated mucus membranes. Use of UDP and ADP for the purpose of treating pulmonary disorders characterized by the retention of lung mucus secretions is described in Patent Application (Boucher, R.C., Jr., et al., PCT/US98/17894). Applicants were motivated to investigate whether UDP and other P2Y₆ receptor agonists could stimulate hydration and mucin production on mucosal surfaces throughout the body, such as in 15 the eye, female reproductive tract, sinonasal and oropharyngeal cavities.

Applicant has discovered that ion, mucin and fluid secretion can be stimulated from mucous membrane tissues via P2Y₆ purinergic receptor-mediated mechanisms. UDP and other purinergic receptor agonists, administered topically or systemically, provide a novel method of treating disorders of mucosal hydration.

20 Applicant has also discovered that UDP and other diphosphate agonists of the P2Y₆ receptor also facilitate expectoration of deep lung mucus. Such expectoration is useful in a method of diagnosing lung diseases whereby the expectorated deep lung mucus is analyzed for cytological abnormalities indicative of lung disease, such as lung cancer and tuberculosis.

25

SUMMARY OF THE INVENTION

A method of stimulating mucosal hydration in a subject in need of such treatment is disclosed. The method of the present invention may be used to increase

mucosal hydration for any reason, including, but not limited to, treatment of dry eye disease, vaginal dryness, rhinosinusitis and dry mouth.

Dry eye disease is defined to include: keratoconjunctivitis sicca (KCS), age-related dry eye, Stevens-Johnson syndrome, Sjogren's syndrome, ocular cicatrical pemphigoid, blepharitis, corneal injury, infection, Riley-Day syndrome, congenital alacrima, nutritional disorders or deficiencies (including vitamin), pharmacologic side effects, eye stress and glandular and tissue destruction, environmental exposure to smog, smoke, excessively dry air, airborne particulates, autoimmune and other immunodeficient disorders, and comatose patients rendered unable to blink. The present invention may also be useful as an ophthalmic wash or irrigation solution in conscious individuals, during surgery (e.g. lasik, radial keratotomy, cataract removal) or to maintain comatose patients or those who cannot blink due to neuromuscular blockade, muscle or nerve damage, or loss of the eyelids. The compound uridine diphosphate (UDP) was found to be a potent stimulator of mucin secretion in tissue preparations containing goblet cells. Furthermore, an *in vivo* example of mucin secretion in accordance with the invention is conducted on an animal using impression cytology.

A method of stimulating cervical and vaginal secretions in a subject in need of such treatment is disclosed. The method of the present invention may be used to increase cervical and vaginal secretions for any reason, including, but not limited to, treatment of vaginal dryness. Vaginal dryness is associated with but not limited to menopause, childbirth, breastfeeding, chemotherapy or radiotherapy, diabetes mellitus, Sjögren's syndrome, Ehlers-Danlos syndrome, systemic sclerosis and other systemic autoimmune diseases, hysterectomy, urogenital surgery, psychosomatic disorders, anxiety, psychosexual problems, and pharmacological drug-related side effects.

Furthermore, because of their general ability to rehydrate mucosal surfaces, the compounds of the present invention may also be useful in the treatment

of rhinosinusitis and dry mouth. Additionally, it is postulated that the compounds of the present invention could be useful for the treatment of dry mouth.

The method of the present invention comprises administering a P2Y₆ receptor agonist: uridine 5'-diphosphate, P¹,P³-di(uridine-5')triphosphate, cytidine 5'-

5 diphosphate or adenosine 5'-diphosphate or analogs thereof, in an amount effective to stimulate mucosal hydration.

Another aspect of the present invention is the use of uridine 5'-diphosphate, P¹,P³-di(uridine-5')triphosphate, cytidine 5'-diphosphate or adenosine 5'-diphosphate or analogs thereof, for the manufacture of a medicament for carrying out a therapeutic 10 method of treatment as given above.

The present invention also discloses pharmaceutical compositions comprising uridine 5'-diphosphate, P¹,P³-di(uridine-5')triphosphate, cytidine 5'-diphosphate or adenosine 5'-diphosphate or analogs thereof, with a pharmaceutical carrier therefor.

The present invention also discloses a method of detecting lung disease 15 comprising administering uridine 5'-diphosphate, P¹,P³-di(uridine-5')triphosphate, cytidine 5'-diphosphate or adenosine 5'-diphosphate or analogs thereof, to at least one lung of an individual in order to facilitate the obtaining of a deep lung mucus, i.e., sputum sample, whereby the sputum sample is subjected to cytological, immunocytochemical, bacterial, or DNA analysis (e.g., via PCR) for detecting 20 cellular abnormalities in the lung epithelium. The lung diseases detectable by this method include, but are not limited to lung cancer and tuberculosis. A preferred diphosphate compound for this diagnostic method is UDP (uridine 5'-diphosphate).

DETAILED DESCRIPTION OF THE INVENTION

25 The method of the present invention may be used to increase mucosal hydration for any reason, including, but not limited to, treatment of dry eye disease, vaginal dryness, rhinosinusitis and dry mouth. Dry eye disease is defined to include: keratoconjunctivitis sicca (KCS), age-related dry eye, Stevens-Johnson syndrome, Sjogren's syndrome, ocular cicatrical pemphigoid, blepharitis, corneal injury,

infection, Riley-Day syndrome, congenital alacrima, nutritional disorders or deficiencies (including vitamin), pharmacologic side effects, eye stress and glandular and tissue destruction, environmental exposure to smog, smoke, excessively dry air, airborne particulates, autoimmune and other immunodeficient disorders, and comatose 5 patients rendered unable to blink. The present invention may also be useful as an ophthalmic wash or irrigation solution in conscious individuals, during surgery or to maintain comatose patients or those who cannot blink due to muscle or nerve damage, neuromuscular blockade or loss of the eyelids.

Applicants have discovered that uridine 5'-diphosphate (UDP) and related 10 compounds are potent agonists for purinergic receptors found in cervical and vaginal mucus membrane preparations. The methods of the present invention are an improvement upon the current most commonly used treatments of vaginal dryness because UDP stimulates a patient's own production and secretion of mucins as well as increasing the levels of mucosal hydration, which serve to maintain the natural 15 protective and lubricant characteristics of vaginal and cervical mucosa. The methods of the present invention may also be used exclusive of, or as an adjunct to, hormone replacement therapy (HRT) or estrogen replacement therapy (ERT).

Another disease state characterized by improper hydration of mucus secretions is sinusitis. Sinusitis is a disease of the paranasal sinuses typically associated with 20 retained, thick mucus secretions.

Dry mouth is a condition in which the mucus membranes of the oropharyngeal cavity becomes dehydrated, leading to discomfort, difficulty swallowing and bad breath. Among the conditions generally referred to as "dry mouth" are, but not limited to: Sjogren's syndrome, chemotherapy and post radiation treatment, and 25 pharmacologic side effects.


Applicant has discovered that uridine 5'-diphosphate (UDP) is a potent agonist for purinergic receptors found in mucus membrane preparations. The method of the present invention is an improvement upon the current most commonly used treatment

of impaired mucosal hydration--artificial tears (i.e., saline solution) for dry eye; oily lubricants for vaginal dryness; saline irrigation or decongestants for sinusitis; artificial saliva or Salagen for dry mouth. Because UDP stimulates a patient's own mucosal hydration mechanisms, it maintains the natural protective and lubricant characteristics. Furthermore, the method of the present invention may be useful even where mucosal glands are dysfunctional or absent.

The present invention also discloses a method of detecting lung disease comprising administering uridine 5'-diphosphate, P¹,P³-di(uridine-5')triphosphate, cytidine 5'-diphosphate or adenosine 5'-diphosphate or analogs thereof, to at least one lung of an individual in order to facilitate the obtaining of a deep lung mucus, i.e., sputum sample, whereby the sputum sample is subjected to cytological, immunocytochemical, bacterial, or DNA analysis (e.g., via PCR) for detecting cellular abnormalities in the lung epithelium. The lung diseases detectable by this method include, but are not limited to lung cancer and tuberculosis. A preferred diphosphate compound for this diagnostic method is UDP (uridine 5'-diphosphate). Prior to analysis of the sputum sample, the sputum sample may first be digested with a liquefying agent, such as N-acetyl-L-cysteine (NALC) and sodium hydroxide.

The present invention provides a method of stimulating mucosal hydration in a mammal, including a human, in need thereof comprising administering an amount of a compound of Formulas I, II, III, or IV or a pharmaceutically acceptable ester or salt thereof effective to increase said hydration.

UDP and its analogs are depicted in general Formula I:

Formula I

wherein:

10 X_1 and X_2 are each independently either O^- or S^- ; preferably, X_1 and X_2 are O^- ;


R_1 is O , imido, methylene or dihalomethylene (e.g., dichloromethylene or difluoromethylene); preferably, R_1 is oxygen or difluoromethylene;

15 R_2 is selected from the group consisting of H , halo, alkyl, substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, alkoxy, nitro and azido; preferably, R_2 is H ; particularly preferred compounds of Formula I are uridine 5'-diphosphate (UDP) and uridine 5'-O-(2-thiodiphosphate) (UDP β S).

A dinucleotide is depicted by the general Formula II:

Formula II

20



25

wherein:

X is oxygen, methylene, difluoromethylene, or imido;

B and B' are each independently a purine residue or a pyrimidine residue linked through the 9- or 1- position, respectively;

5 Z = OH or N₃;

Z' = OH or N₃;

Y = H or OH;

Y' = H or OH;

provided that when Z is N₃, Y is H or when Z' is N₃, Y' is H.

The furanose sugar is preferably in the β -configuration.


The furanose sugar is most preferably in the β -D-configuration.

10

Preferred compounds of Formula II are the compounds of Formula IIa:

Formula IIa

15



wherein:

X=O;

20 Z, Z', Y, and Y'=OH;

B and B' are defined in Formulas IIc and IIId;

25

X=O;

Z, Z', Y, and Y'=OH;

B=uracil;

B' is defined in Formulas IIc and IIId; or

X=O;

Z, Y, and Y'=OH;

Z'=H;

B=uracil;

B' is defined in Formulas IIc and IIId; or

5

X=O;

Z and Y=OH;

Z'=N₃;

Y'=H;

10

B=uracil;

B'=thymine; or

X=O;

Z and Z'=N₃;

15

Y and Y'=H;

B and B'=thymine; or

X=CH₂, CF₂, or NH;

Z, Z', Y, and Y'=OH;


20

B and B' are defined in Formulas IIc and IIId.

Another preferred group of the compounds of Formula II are the compounds of Formula IIb or the pharmaceutically acceptable salts thereof:

Formula IIb

25



wherein:


X is oxygen, methylene, difluoromethylene, or imido; and

B and B' are each independently a purine residue, as in Formula IIc, or a pyrimidine residue, as in Formula IId, linked through the 9- or 1- position, respectively.

5 In the instance where B and B' are uracil, attached at N-1 position to the ribosyl moiety, then the total of m + n may equal 3 or 4 when X is oxygen. The ribosyl moieties are in the D- configuration, as shown, but may be L-, or D- and L-. The D- configuration is preferred.

10

Formula IIc



15 wherein

R₁ is hydrogen, C₁₋₈alkyl, C₃₋₆ cycloalkyl, phenyl, or phenoxy; wherein at

least one hydrogen of said C₁₋₈alkyl, phenyl, phenoxy, is optionally substituted with a moiety selected from the group consisting of halogen, hydroxy, C₁₋₄alkoxy, C₁-

alkyl, C₆₋₁₀aryl, carboxy, cyano, nitro, sulfonamido, sulfonate, phosphate, sulfonic

20 acid, amino, C₁₋₄ alkylamino, di-C₁₋₄ alkylamino wherein said alkyl groups are

optionally linked to form a heterocycle, ω -A(alkyl)CONH(alkyl)-, and ω -

A(alkyl)NHCO(alkyl)-, wherein A is amino, mercapto, hydroxy or carboxyl;

R₂ is O or is absent; or

R₁ and R₂ taken together form a 5-membered fused imidazole ring optionally

substituted on the 4- or 5- positions of the etheno moiety with C₁₋₄alkyl, phenyl or phenoxy, wherein at least one hydrogen of said C₁₋₄alkyl, phenyl, phenoxy, is optionally substituted with a moiety selected from the group consisting of halogen, hydroxy, C₁₋₄alkoxy, C₁₋₄alkyl, C₆₋₁₀aryl, C₇₋₁₂arylalkyl, carboxy, cyano, nitro,

5 sulfonamido, sulfonate, phosphate, sulfonic acid, amino, C₁₋₄ alkylamino, and di-C₁₋₄ alkylamino wherein said dialkyl groups are optionally linked to form a heterocycle; and

R₃ is hydrogen, NH₂, C₁₋₈alkyl, C₃₋₆ cycloalkyl, phenyl; or phenoxy; wherein at least one hydrogen of said NH₂, C₁₋₈ alkyl, phenyl, or phenoxy, is optionally


10 substituted with a moiety selected from the group consisting of halogen, hydroxy, C₁₋₄alkyl, C₆₋₁₀aryl, C₇₋₁₂arylalkyl, C₁₋₄alkoxy, C₇₋₁₂arylalkyloxy, C₁₋₄alkylthio, phenylthio, C₇₋₁₂arylalkylthio, carboxy, cyano, nitro, sulfonamido, sulfonate, phosphate, sulfonic acid, amino, C₁₋₄ alkylamino, phenylamino, C₇₋₁₂arylalkyamino, di-C₁₋₄ alkyl amino wherein said dialkyl groups are optionally linked to form a heterocycle, ω -

15 A(alkyl)CONH(alkyl)B-, and ω -A(alkyl)NHCO(alkyl)B-, wherein A and B are independently amino, mercapto, hydroxy or carboxyl.

The substituted derivatives of adenine (Formula IIc) include adenine 1-oxide; 1,N6-(4- or 5-substituted etheno) adenine; 6-substituted adenine; or 8-substituted aminoadenine, [6-aminohexyl]carbamoylmethyl-adenine; and ω -acylated-

20 amino(hydroxy, thiol and carboxy)alkyl(C₂₋₁₀)-adenine, wherein the acyl group is chosen from among, but not limited to, acetyl, trifluororoacetyl, benzoyl, substituted-benzoyl, etc., or the carboxylic moiety is present as its ester or amide derivative, for example, the ethyl or methyl ester or its methyl, ethyl or benzamido derivative.

Likewise, B or B' or both in Formula IIb may be a pyrimidine with the general formula of Figure IIId, linked through the 1-position:

Formula IIId

5

wherein:

R_4 is hydrogen, hydroxy, mercapto, amino, cyano, C_{7-12} arylalkoxy, C_{1-6} alkylthio, C_{1-6} alkoxy, C_{1-6} alkylamino or di C_{1-4} alkylamino, wherein the alkyl groups are optionally linked to form a heterocycle;

10 R_5 is hydrogen, acetyl, benzoyl, C_{1-6} alkyl, phenoxy, C_{1-5} alkanoyl, aroyl, or sulphonate;

R_6 is hydroxy, mercapto, C_{1-4} alkoxy, C_{7-12} arylalkoxy, C_{1-6} alkylthio, amino, S-phenyl, C_{1-5} disubstituted amino, triazolyl, C_{1-6} alkylamino, or di- C_{1-4} alkylamino wherein said dialkyl groups are optionally linked to form a heterocycle or linked to N^3

15 to form a substituted ring; or

R_5 and R_6 taken together form a 5-membered fused imidazole ring between positions 3 and 4 of the pyrimidine ring and form a 3, N^4 -ethenocytosine derivative, wherein said etheno moiety is optionally substituted on the 4- or 5- positions with C_{1-4} alkyl; phenyl; or phenoxy; wherein at least one hydrogen of said C_{1-4} alkyl; phenyl or

20 phenoxy is optionally substituted with a moiety selected from the group consisting of halogen, hydroxy, C_{1-4} alkoxy, C_{1-4} alkyl, C_{6-10} aryl, C_{7-12} arylalkyl, carboxy, cyano, nitro, sulfonamido, sulfonate, phosphate, sulfonic acid, amino, C_{1-4} alkylamino, and di- C_{1-4} alkylamino wherein said dialkyl groups are optionally linked to form a heterocycle;

R_7 is hydrogen, hydroxy, cyano, nitro, or C_{2-8} alkenyl; wherein said alkenyl moiety is optionally linked through an oxygen to form a ring, wherein at least one hydrogen of said alkenyl moiety on the carbon adjacent to said oxygen is optionally substituted with C_{1-6} alkyl, phenyl, substituted C_{2-8} alkynyl, halogen, substituted C_{1-6} alkyl, CF_3 , C_{2-3} alkenyl, C_{2-3} alkynyl, allylamino, bromovinyl, ethyl propenoate, or propenoic acid; or

R_6 and R_7 together form a 5 or 6-membered saturated or unsaturated ring bonded through N or O at R_6 , such ring optionally contains substituents that themselves contain functionalities; provided that when R_8 is amino or substituted 10 amino, R_7 is hydrogen; and

R_8 is hydrogen, amino or di- C_{1-4} alkylamino, C_{1-4} alkoxy, C_{7-12} arylalkoxy, C_{1-4} alkylthio, C_{7-12} arylalkylthio, carboxamidomethyl, carboxymethyl, methoxy, methylthio, phenoxy or phenylthio.

In the general structure of Figure IIc above, the dotted lines in the 2- to 6-positions are intended to indicate the presence of single or double bonds in these 15 positions; the relative positions of the double or single bonds being determined by whether the R_4 , R_6 , and R_7 substituents are capable of keto-enol tautomerism.

In the general structures of Figure IIc and IIId above, the acyl groups advantageously comprise alkanoyl or aroyl groups. The alkyl groups advantageously 20 contain 1 to 8 carbon atoms, particularly 1 to 4 carbon atoms optionally substituted by one or more appropriate substituents, as described below. The aryl groups including the aryl moieties of such groups as aryloxy are preferably phenyl groups optionally substituted by one or more appropriate substituents, as described below. The above-mentioned alkenyl and alkynyl groups advantageously contain 2 to 8 carbon atoms, 25 particularly 2 to 6 carbon atoms, e.g., ethenyl or ethynyl, optionally substituted by one or more appropriate substituents as described below. Appropriate substituents on the above-mentioned alkyl, alkenyl, alkynyl, and aryl groups are advantageously selected from halogen, hydroxy, C_{1-4} alkoxy, C_{1-4} alkyl, C_{6-12} arylalkoxy, carboxy, cyano, nitro,


sulfonamido, sulfonate, phosphate, sulfonic, amino, and substituted amino wherein the amino is singly or doubly substituted by a C₁₋₄ alkyl, and when doubly substituted, the alkyl groups optionally being linked to form a heterocycle.

5

CDP and its analogs are depicted by general Formula III:

Formula III

10



15

wherein:

R₁, X₁ and X₂ are defined as in Formula I;

R₅ and R₆ are H while R₇ is nothing and there is a double bond between N-3 and C-4 (cytosine), or

20


R₅, R₆ and R₇ taken together are -CH=CH-, forming a ring from N-3 to N-4 with a double bond between N-4 and C-4 (3,N⁴-ethenocytosine) optionally substituted at the 4- or 5-position of the etheno ring.

ADP and its analogs are depicted by general Formula IV:

25

Formula IV

5



wherein:

R₁, X₁ and X₂ are defined as in Formula I;10 R₃ and R₄ are H while R₂ is nothing and there is a double bond between N-1 and C-6 (adenine), orR₃ and R₄ are H while R₂ is O and there is a double bond between N-1 and C-6 (adenine 1-oxide), or15 R₃, R₄, and R₂ taken together are -CH=CH-, forming a ring from N-6 to N-1 with a double bond between N-6 and C-6 (1,N6-ethenoadenine).

For simplicity, Formulas I, II, III, and IV herein illustrate the active compounds in the naturally occurring D-configuration, but the present invention also encompasses compounds in the L-configuration, and mixtures of compounds in the D- and L-configurations, unless otherwise specified. The naturally occurring 20 D-configuration is preferred.

The compounds of the invention may be present in the form of their pharmaceutically acceptable salts, such as, but not limited to, an alkali metal salt such as sodium or potassium; an alkaline earth metal salt such as manganese, magnesium, or calcium; or an ammonium or tetraalkyl ammonium salt, i.e., NX₄⁺ (wherein X is C₁-4). Pharmaceutically acceptable salts are salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects.

The compounds of the invention may also be present in the form of prodrugs, typically comprising esters or amide moieties on the heterocyclic and furanosyl hydroxyls of the compound.

Another aspect of the present invention is a method of treating a mammal with vaginal dryness arising from, but not limited to, menopause, childbirth, breastfeeding, chemotherapy or radiotherapy, diabetes mellitus, Sjögren's syndrome, Ehlers-Danlos syndrome, systemic sclerosis and other systemic autoimmune diseases, hysterectomy, urogenital surgery, psychosomatic disorders, anxiety, psychosexual problems, and pharmacological drug-related side effects.

10 The present invention further provides pharmaceutical compositions comprising a P2Y₆ receptor agonist selected from the group consisting of general Formula I, i.e., uridine 5'-diphosphate [UDP] and its analogs, general Formula II, i.e., P¹,P⁴-di(uridine-5') triphosphate [U₂P₃] and its analogs, general Formula III, i.e., cytidine 5'-diphosphate [CDP] and its analogs, and general Formula IV, i.e., 15 adenosine 5'-diphosphate [ADP] and its analogs, together with a pharmaceutical carrier therefor.

The compounds disclosed herein may be administered to the mucosa of a patient by any suitable means, but are preferably administered by a solution, gel, suspension, cream, foam, pessary, or tablet containing the active compound.

20 Alternatively, the active compounds may be administered by continuous release from a vaginal ring (P. Stumpf, *Obstet. Gynecol.* 75:9S (1990)) or an intrauterine device (K. Andersson, et al., *Obstet. Gynecol.* 79:963 (1992)).

The active compounds disclosed herein may be administered to the eyes of a patient by any suitable means, but are preferably administered by administering a 25 liquid or gel suspension of the active compound in the form of drops, spray or gel. Alternatively, the active compounds may be applied to the eye via liposomes. Further, the active compounds may be infused onto the mucosal surface via a pump-catheter system. Another embodiment of the present invention involves the

active compound contained within a continuous or selective-release device, for example, membranes such as, but not limited to, those employed in the Ocusert™ System (Alza Corp., Palo Alto, CA). As an additional embodiment, the active compounds can be contained within, carried by, or attached to contact lenses which 5 are placed on the eye. Another embodiment of the present invention involves the active compound contained within a swab or sponge which can be applied to the ocular surface. Another embodiment of the present invention involves the active compound contained within a liquid spray which can be applied to the ocular surface.

The topical solution, gel, jelly, ointment, cream, foam, pessary, or tablet 10 contain the active compound in a physiologically compatible vehicle, as those skilled in the art of topical delivery system development can select using conventional criteria.

Solutions formulated for administration to the vagina are usually referred to as 15 irrigations. These are sterile solutions, prepared in a manner typical of sterile injections that are intended for prepared as a single use sterile solution.

Gels or jellies may be produced using a suitable gelling agent including, but not limited to, gelatin, tragacanth, or a cellulose derivative and may include glycerol as a humectant, emollient, and preservative.

Ointments are semi-solid preparations that consist of the active ingredient 20 incorporated into a fatty, waxy, or synthetic base.

Examples of suitable creams include, but are not limited to, water-in-oil and oil-in-water emulsions. Water-in-oil creams may be formulated by using a suitable emulsifying agent with properties similar, but not limited, to those of the fatty alcohols such as cetyl alcohol or cetostearyl alcohol and to emulsifying wax. Oil-in- 25 water creams may be formulated using an emulsifying agent such as cetomacrogol emulsifying wax. Suitable properties include the ability to modify the viscosity of the emulsion and both physical and chemical stability over a wide range of pH. The water

soluble or miscible cream base may contain a preservative system and may also be buffered to maintain an acceptable physiological pH.

Foam preparations may be formulated to be delivered from a pressurized aerosol canister, via a suitable applicator, using inert propellants. Suitable excipients 5 for the formulation of the foam base include, but are not limited to, propylene glycol, emulsifying wax, cetyl alcohol, and glyceryl stearate. Potential preservatives include methylparaben and propylparaben.

Pessaries are solid unit-dose forms suitably shaped for insertion into the vagina and may either be composed of a base that melts at body temperature or which 10 dissolves when in contact with mucous secretions. Examples of suitable bases include, but are not limited to, theobroma oil, synthetic fat bases (e.g. Witepsol), polyethylene glycols (macrogols), and glycerol suppository basis.

Tablets are composed of the active ingredient contained within a solid dosage form base which may include, but not be limited to, excipients such as lactose, 15 microcrystalline cellulose, corn starch, magnesium stearate, silicon dioxide, and hydroxypropyl methylcellulose.

An alternative method of administering the compounds of the present invention is intraoperative instillation during surgical procedures involving mucosal surfaces of the eye, sinuses, mouth and female reproductive tract.

20 In addition to the topical method of administration described above, there are various methods of administering the compounds of the present invention systemically. One such means would involve an aerosol suspension of respirable particles comprised of the active compound, which the subject inhales. The active compound would be absorbed into the bloodstream via the lungs and contact the 25 cervical and/or vaginal tissues in a pharmaceutically effective amount. The respirable particles may be liquid or solid, with a particle size sufficiently small to pass through the mouth and larynx upon inhalation; in general, particles ranging from about 1 to 10 microns, but more preferably 1-5 microns, in size are considered respirable.

Another means of systemically administering the active compounds to the mucosal tissues of the subject would involve administering a liquid/liquid suspension in the form of nasal drops of a liquid formulation, or a nasal spray of respirable particles which the subject inhales. Liquid pharmaceutical compositions of the active compound for producing a nasal spray or nasal drops may be prepared by combining the active compound with a suitable vehicle, such as sterile pyrogen free water or sterile saline by techniques known to those skilled in the art.

Other means of systemic administration of the active compound would involve oral administration, in which pharmaceutical compositions containing compounds of Formulas I, II, III, or IV are in the form of tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents, and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate, or sodium phosphate; granulating and disintegrating agents, for example, corn starch or alginic acid; binding agents, for example, starch, gelatin, or acacia; and lubricating agents, for example magnesium stearate, stearic acid, or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate, or kaolin, or as soft

gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin, or olive oil.

Additional means of systemic administration of the active compound to the cervical and vaginal tissues of the subject would involve a suppository form of the 5 active compound, such that a therapeutically effective amount of the compound reaches the mucosal tissues via systemic absorption and circulation.

For the above mentioned indications, the quantity of the active compound included in the pharmaceutical composition is an amount sufficient to achieve 10 concentrations of the active compound on the mucosa of the subject of from about 10^{-7} to about 10^{-1} Moles/liter, and more preferably from about 10^{-6} to about 10^{-1} Moles/liter.

Depending upon the solubility of the particular formulation of active compound administered, the daily dose to promote tear secretion may be divided among one or several unit dose administrations. The total daily dose for UDP (for 15 example) may range from 0.2 mg to 300 mg, depending upon the age and condition of the subject. A currently preferred unit dose for UDP is about 0.1 to 50 milligrams given at a regimen of 2 to 6 administrations per day.

Depending on the solubility of the particular formulation of active compound administered, the daily dose to promote mucous membrane mucin production and/or 20 hydration may be divided among one or several unit dose administrations. The total daily dose for UDP (for example) may range from 1 to 1000 milligrams, depending upon the age and state of the subject, given at a regimen of up to four times per day or on an as needed basis to address acute exacerbations.

Some compounds of Formulas I, II, III, and IV can be made by methods which 25 are well known to those skilled in the art and in accordance with known procedures (P. Zamecnik, et al., *Proc. Natl Acad. Sci. USA* 89:838-842 (1981); K. Ng et al., *Nucleic Acids Res.* 15:3572-3580 (1977); K. M. Jacobus, et al., U.S. Patent No. 5,789,391 and W. Pendergast, et al., International Patent No. WO98/34942; Boucher,

RC, Jr. et al., PCT/US98/17894) which are incorporated herein by reference; some are commercially available, for example, from Sigma Chemical Company, PO Box 14508, St. Louis, MO 63178. The synthetic methods of U.S. Patent No. 5,789,391 and International Patent No. WO98/34942 are incorporated herein by reference.

5

Example 1:

UDP Stimulates Mucin Release From Human Mucosal Epithelial Cell Culture

The following is an example showing mucin release in response to UDP in an
10 *in vitro* cell culture system containing mucosal epithelial and goblet cells. Mucins, a family of high-molecular-weight glycoproteins secreted by goblet and non-goblet epithelial cells of mucus membranes, are responsible for mucosal hydration. The objective of this study was to demonstrate the effect of UDP on mucin release in Normal Human Bronchial/Tracheal Epithelial cells (NHTBE).

15 NHTBE cells were obtained from a commercial source (Clonetics; CC-2540). The cells are donor specific (non-smoker) and shipped as cryopreserved primary cultures. Bronchial/Epithelial Growth Media (BEGM; Clonetics; CC-3170) was used for expansion. The BEGM media supplied was modified as follows: The level of EGF (Intergen; #4110-80) was increased to a final concentration of 25 ng/ml; the
20 level of Bovine Pituitary Extract (BPE, Clonetics, CC 4009) was increased to 0.13 mg/ml; the level of retinoic acid (Sigma; R-2625) was increased to a final concentration of 5×10^{-8} M. The cells for the expansion phase were seeded at 500 cells/cm². Media was changed after 24 hours and every 48 hours thereafter until cells are 75% confluent (5-14 days). It was important not to exceed 75% confluency. Cells
25 were dissociated with trypsin. Once collected, cells were stored in liquid nitrogen at passage-2 [Freezing solution: 80% media (BEGM), 10% FBS, 10% sterile DMSO].

NHTBE cells must undergo a program of differentiation in order to achieve a mucin-secreting phenotype. This was achieved by culturing cells on porous

membrane cell culture inserts (Transwell™; 12 mm, 0.45 µm pore size, Corning-Costar #3460) ultimately under conditions of an air/liquid interface. The insert membrane was first coated with rat tail collagen (Collaborative Biomedical Products #40236) as follows: 235µl of coating solution(50 µg/ml of rat tail collagen dissolved in 0.02N acetic acid) was added to apical surface of insert. The insert was allowed to dry at room temperature for one hour in tissue culture hood and then washed once with 500µl of PBS containing nystatin (20,000 units/liter sigma;N-1638) and gentamicin (100µg/ml). Next, the 500µl PBS was aspirated and the inserts equilibrated with BEGM media in the apical and basal compartments; incubated for 5 one hour. Frozen NHTBE cells were thawed rapidly and seeded on the collagen-coated inserts at 20,000 cells/cm². Media was changed after 24 hours and every 48 hours thereafter until the cells were 60-75% confluent (5-7 days in culture). At this point, the cultures were switched to air-liquid interface by removing the media bathing the apical aspect of the cells. The media bathing the basolateral aspect of the 10 culture must be changed daily until the time of experiment. The composition of this 15 ALI media was as follows: A 1:1 mixture of Bronchial epithelial cell growth medium: Dulbecco's Modified Eagles medium with high glucose (BEGM: DMEM-H), containing final concentration of 0.5 ng/ml hrEGF, 0.5 µ/ml hydrocortisone, 5µg/ml insulin, 10µg/ml transferrin, 0.5µg/ml epinephrine, 6.5 ng/ml triiodothyronine, 20 50µg/ml gentamicin, 50 ng/ml amphotericin-B (all supplied by Clonetics as SingleQuots), 8 mg/ml BPE, 5 x 10⁻⁸ M all-trans retinoic acid (Sigma #R-2625), 1.5µg/ml BSA (Intergen, #3310-80), and 20 U/ml nystatin (Sigma #N-1638). SingleQuots can be purchased separately from Clonetics (# CC-4175). As has been 25 reported by Gray, et al., *Am J. Resp. Cell Molec. Biol.* 14(1):104-112 (1996), mucin phenotype was seen by 14 days in culture (7 days of air/liquid interface), and cilia were apparent by 21 days in culture (14 days of air/liquid interface).

Ascites fluid containing the anti-mucin antibody designated 17Q2 IgG was kindly provided by Professor Reen Wu; (Department of Internal Medicine, University


of California at Davis). 17Q2 antibody was purified with a Protein G column (Pierce #44441). Alkaline phosphatase was conjugated to 17Q2 antibody using the EZ-Link Maleimide Activated Alkaline Phosphatase kit (Pierce #31486).

UDP (10^{-8} ~ 10^{-4}) was added to the apical aspect of the differentiated cultures

5 At the end of the incubation period (two hours) the stimulation media was removed and stored at -80° C until analysis for mucin content. Mucin was quantitated by ELISA as described above.

UDP stimulated the release of mucin glycoproteins from differentiated cultures of human airway epithelium (Fig. 1) in a concentration-dependent manner.

10 The EC₅₀ was calculated to be 5.55×10^{-7} M.



Example 2:

Stimulation of Mucin Release from Mucosal Goblet Cells

The following is an example of a method for measuring the effects of UDP

15 and analogs *in vivo* on mucin secretion from mucous membranes using impression

cytology. Impression cytology is a technique used to stain and identify mucin-containing goblet cells (Rolando, M., et al., *Adv. Exp. Med. Bio.* 350:249 (1994)).

UDP or saline solution is applied to the mucosal surface and impression cytology is performed 5, 15, 30 and 60 minutes after application of solution. The 5 specimens are stained with periodic acid and Schiff's reagent (AB-PAS), and the area of PAS staining is analyzed by computer software (Winroo or BioQuant). A decrease in the area of AB-PAS staining compared to saline control indicates that UDP stimulates mucin secretion from goblet cells of mucus membranes.

The present invention is concerned primarily with the treatment of human 10 subjects, but may also be employed for the treatment of other mammalian subjects, such as dogs and cats, for veterinary purposes.

The topical solution containing the active compound may also contain a physiologically compatible vehicle, as those skilled in the ophthalmic art can select using conventional criteria. The vehicles may be selected from the known ophthalmic 15 vehicles which include, but are not limited to, saline solution, water polyethers such as polyethylene glycol, polyvinyls such as polyvinyl alcohol and povidone, cellulose derivatives such as methylcellulose and hydroxypropyl methylcellulose, petroleum derivatives such as mineral oil and white petrolatum, animal fats such as lanolin, polymers of acrylic acid such as carboxypolymethylene gel, vegetable fats such as 20 peanut oil and polysaccharides such as dextrans, and glycosaminoglycans such as sodium hyaluronate and salts such as sodium chloride and potassium chloride.

An alternative method of administering the compounds of the present invention is intraoperative instillation during surgical procedures involving mucosal surfaces of the eye, sinuses, mouth and female reproductive tract.


25 The invention and the manner and process of making and using it are now described in such full, clear, concise and exact terms as to enable any person skilled in the art to which it pertains, to make and use the same. It is to be understood that the foregoing describes preferred embodiments of the present invention and that

modifications may be made therein without departing from the spirit or scope of the present invention as set forth in the claims. To particularly point out and distinctly claim the subject matter regarded as invention, the following claims conclude this specification.

WHAT IS CLAIMED IS:

1. A method of stimulating mucosal hydration in a mammal in need thereof comprising administering an effective hydration increasing amount of a
5 compound of Formulas I, II, III or IV:

Formula I




wherein:

X_1 and X_2 are each independently either O^- or S^- .

15 R₁ is O, imido, methylene or dihalomethylene;

R_2 is selected from the group consisting of H, halo, alkyl, substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, alkoxy, nitro and azido;

Formula II



25

wherein:

X is oxygen, methylene, difluoromethylene, or imido;

B and B' are each independently a purine residue or a pyrimidine residue linked through the 9- or 1- position, respectively;

5 Z = OH or N₃;

 Z' = OH or N₃;


 Y = H or OH;

 Y' = H or OH;

provided that when Z is N₃, Y is H or when Z' is N₃, Y' is H;

Formula IIa

10



15 wherein:

X=O;

Z, Z', Y, and Y'=OH;

B and B' are defined in Formulas IIc and IIId;

20

X=O;

Z, Z', Y, and Y'=OH;

B=uracil;

B' is defined in Formulas IIc and IIId; or

25

X=O;

Z, Y, and Y'=OH;

Z'=H;

B=uracil;

B' is defined in Formulas IIc and IIId; or

X=O;

Z and Y=OH;

Z'=N₃;

5 Y'=H;

B=uracil;

B'=thymine; or

X=O;

10 Z and Z'=N₃;

Y and Y'=H;

B and B'=thymine; or


X=CH₂, CF₂, or NH;

15 Z, Z', Y, and Y'=OH;

B and B' are defined in Formulas IIc and IIId;

Formula IIc

20



wherein

25 R₁ is hydrogen, C₁₋₈alkyl, C₃₋₆ cycloalkyl, phenyl, or phenoxy; wherein at

least one hydrogen of said C₁₋₈alkyl, phenyl, phenoxy, is optionally substituted with a moiety selected from the group consisting of halogen, hydroxy, C₁₋₄alkoxy, C₁₋₄alkyl,

C₆₋₁₀aryl, carboxy, cyano, nitro, sulfonamido, sulfonate, phosphate, sulfonic acid, amino, C₁₋₄ alkylamino, di-C₁₋₄ alkylamino wherein said alkyl groups are

5 optionally linked to form a heterocycle, ω -A(alkyl)CONH(alkyl)-, and ω -A(alkyl)NHCO(alkyl)-, wherein A is amino, mercapto, hydroxy or carboxyl;

R₂ is O or is absent; or

R₁ and R₂ taken together form a 5-membered fused imidazole ring optionally substituted on the 4- or 5- positions of the etheno moiety with C₁₋₄alkyl, phenyl or

10 phenoxy, wherein at least one hydrogen of said C₁₋₄alkyl, phenyl, phenoxy, is optionally substituted with a moiety selected from the group consisting of halogen,

hydroxy, C₁₋₄alkoxy, C₁₋₄alkyl, C₆₋₁₀aryl, C₇₋₁₂arylalkyl, carboxy, cyano, nitro,

sulfonamido, sulfonate, phosphate, sulfonic acid, amino, C₁₋₄ alkylamino, and di-C₁₋₄ alkylamino wherein said dialkyl groups are optionally linked to form a heterocycle;

15 and


R₃ is hydrogen, NH₂, C₁₋₈alkyl, C₃₋₆ cycloalkyl, phenyl; or phenoxy; wherein at least one hydrogen of said NH₂, C₁₋₈ alkyl, phenyl, or phenoxy, is optionally substituted with a moiety selected from the group consisting of halogen, hydroxy, C₁₋₄alkyl,

C₆₋₁₀aryl, C₇₋₁₂arylalkyl, C₁₋₄alkoxy, C₇₋₁₂arylalkyloxy, C₁₋₄alkylthio, phenylthio,

20 C₇₋₁₂arylalkylthio, carboxy, cyano, nitro, sulfonamido, sulfonate, phosphate, sulfonic acid, amino, C₁₋₄ alkylamino, phenylamino, C₇₋₁₂arylalkyamino, di-C₁₋₄ alkyl amino

wherein said dialkyl groups are optionally linked to form a heterocycle, ω -

A(alkyl)CONH(alkyl)B-, and ω -A(alkyl)NHCO(alkyl)B-, wherein A and B are independently amino, mercapto, hydroxy or carboxyl;

Formula IIId

5 wherein:

R_4 is hydrogen, hydroxy, mercapto, amino, cyano, C_{7-12} arylalkoxy, C_{1-6} alkylthio, C_{1-6} alkoxy, C_{1-6} alkylamino or di C_{1-4} alkylamino, wherein the alkyl groups are optionally linked to form a heterocycle;

10 R_5 is hydrogen, acetyl, benzoyl, C_{1-6} alkyl, phenoxy, C_{1-5} alkanoyl, aroyl, or sulphonate;

R_6 is hydroxy, mercapto, C_{1-4} alkoxy, C_{7-12} arylalkoxy, C_{1-6} alkylthio, amino, S-phenyl, C_{1-5} disubstituted amino, triazolyl, C_{1-6} alkylamino, or di- C_{1-4} alkylamino wherein said dialkyl groups are optionally linked to form a heterocycle or linked to N^3 to form a substituted ring; or

15 R_5 and R_6 taken together form a 5-membered fused imidazole ring between positions 3 and 4 of the pyrimidine ring and form a 3, N^4 -ethenocytosine derivative, wherein said etheno moiety is optionally substituted on the 4- or 5- positions with C_{1-4} alkyl; phenyl; or phenoxy; wherein at least one hydrogen of said C_{1-4} alkyl; phenyl or phenoxy is optionally substituted with a moiety selected from the group consisting 20 of halogen, hydroxy, C_{1-4} alkoxy, C_{1-4} alkyl, C_{6-10} aryl, C_{7-12} arylalkyl, carboxy, cyano, nitro, sulfonamido, sulfonate, phosphate, sulfonic acid, amino, C_{1-4} alkylamino, and di- C_{1-4} alkylamino wherein said dialkyl groups are optionally linked to form a heterocycle;

25 R_7 is hydrogen, hydroxy, cyano, nitro, or C_{2-8} alkenyl; wherein said alkenyl moiety is optionally linked through an oxygen to form a ring, wherein at least one


hydrogen of said alkenyl moiety on the carbon adjacent to said oxygen is optionally substituted with C₁₋₆alkyl, phenyl, substituted C₂₋₈alkynyl, halogen, substituted C₁₋₄alkyl, CF₃, C₂₋₃alkenyl, C₂₋₃alkynyl, allylamino, bromovinyl, ethyl propenoate, or propenoic acid; or

5 R₆ and R₇ together form a 5 or 6-membered saturated or unsaturated ring bonded through N or O at R₆, such ring optionally contains substituents that themselves contain functionalities; provided that when R₈ is amino or substituted amino, R₉ is hydrogen; and

R₈ is hydrogen, amino or di-C₁₋₄alkylamino, C₁₋₄alkoxy, C₇₋₁₂arylalkoxy, C₁₋₄alkylthio, C₇₋₁₂arylalkylthio, carboxamidomethyl, carboxymethyl, methoxy, methylthio, phenoxy or phenylthio.


2. The method of claim 1 wherein B and B' are independently compounds of Formulas IIc and IIId:

15



Formula IIId

20



wherein:

R_4 is hydroxy, mercapto, amino, cyano, aralkoxy, C_{1-6} alkoxy, C_{1-6} alkylamino, and dialkylamino, the alkyl groups optionally linked to form a heterocycle;

5 R_5 is hydrogen, acyl, C_{1-6} alkyl, aroyl, C_{1-5} alkanoyl, benzoyl, or sulphonate;

R_6 is hydroxy, mercapto, alkoxy, aralkoxy, C_{1-6} -alkylthio, C_{1-5} disubstituted amino, triazolyl, alkylamino, or dialkylamino, where the alkyl groups are optionally linked to form a heterocycle or linked to N-3 to form an optionally substituted ring;

10 R_7 is hydrogen, hydroxy, cyano, nitro, alkenyl, with the alkenyl moiety optionally linked through oxygen to form a ring optionally substituted on the carbon adjacent to the oxygen with alkyl or aryl groups, substituted alkynyl or hydrogen where R_8 is amino or substituted amino and halogen, alkyl, substituted alkyl, perhalomethyl C_{2-6} alkyl, C_{2-3} alkenyl, or substituted ethenyl (e.g., allylamino, 15 bromvinyl and ethyl propenoate, or propenoic acid), C_{2-3} alkynyl or substituted alkynyl when R_6 is other than amino or substituted amino and together R_5 - R_6 may form a 5- or 6-membered saturated or unsaturated ring bonded through N or O at R_6 , such a ring may contain substituents that themselves contain functionalities;

R_8 is hydrogen, alkoxy, arylalkoxy, alkylthio, arylalkylthio, 20 carboxamidomethyl, carboxymethyl, methoxy, methylthio, phenoxy, or phenylthio; or pharmaceutically acceptable ester or salt thereof.

3. The method of claim 1 or 2, wherein the effective hydration increasing amount of compound of Formulas I, II, III or IV is administered to the eyes to treat dry eye 25 disease.

4. The method of claim 1 or 2, wherein the effective hydration increasing amount of compound of Formulas I, II, III or IV is administered to the sinuses to treat rhinosinusitis.
5. 5. The method of claim 1 or 2, wherein the effective hydration increasing amount of compound of Formulas I, II, III or IV is administered to the mouth to treat dry mouth disease.
6. The method of claim 1 or 2, wherein the effective hydration increasing amount of compound of Formulas I, II, III or IV is administered to the eyes to treat corneal injury.
7. The method of claim 1 or 2, wherein the effective hydration increasing amount of compound of Formulas I, II, III or IV is administered to the vagina to treat vaginal dryness.
8. The method of claim 3, wherein a preferred compound is UDP.
9. The method of facilitating the expectoration of a sputum sample for the purpose of detecting cellular abnormalities in the deep lung epithelia cells contained in the sputum, wherein the cellular abnormalities are indicative of lung disease, said method comprising administering to at least one lung of a subject an expectoration increasing amount of a compound of Formulas I, II, III or IV.
- 25 10. The method of claim 9, wherein the lung disease is selected from the group comprising lung cancer and tuberculosis.

11. The method of claim 9, wherein the analysis of the sputum comprises cytological analysis, immunocytochemical analysis, bacterial analysis and DNA analysis.

5 12. The method of claim 9, wherein a preferred compound is UDP.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 August 2000 (31.08.2000)

PCT

(10) International Publication Number
WO 00/50024 A3

(51) International Patent Classification⁷: **A61K 31/70, A61P 43/00**

(81) Designated States (national): AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW.

(21) International Application Number: **PCT/US00/05282**

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date: 25 February 2000 (25.02.2000)

Published:

— With international search report.

(25) Filing Language: **English**

(88) Date of publication of the international search report:
5 July 2001

(26) Publication Language: **English**

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(30) Priority Data:

60/121,754 26 February 1999 (26.02.1999) US

(71) Applicant (for all designated States except US): **INSPIRE PHARMACEUTICALS, INC. [US/US]; Suite 470, 4222 Emperor Boulevard, Durham, NC 27703 (US).**

(72) Inventors; and

(75) Inventors/Applicants (for US only): **YERXA, Benjamin, R. [US/US]; 1330 Hathaway Road, Raleigh, NC 22608 (US). RIDOUT, Janet, L. [US/US]; 3101 Morningside Drive, Raleigh, NC 27607-3010 (US). JONES, Arthur, C. [US/US]; 5 Winnabow Court, Durham, NC (US).**

(74) Agent: **HALLUIN, Albert, P.; Howrey Simon Arnold & White, LLP, 1299 Pennsylvania Avenue, N.W., Washington, DC 20004 (US).**

WO 00/50024 A3

(54) Title: **METHOD OF PROMOTING MUCOSAL HYDRATION WITH CERTAIN URIDINE, ADENINE AND CYTIDINE DIPHOSPHATES AND ANALOGS THEREOF**

(57) Abstract: A method and preparation for the stimulation of mucosal hydration in a subject in need of such treatment is disclosed. The method comprises administering to the mucosal surfaces of the subject a purinergic receptor agonist such as uridine 5'-diphosphate (UDP), dinucleotides, cytidine 5'-diphosphate (CDP), adenosine 5'-diphosphate (ADP), or their therapeutically useful analogs and derivatives, in an amount effective to stimulate mucin secretion. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include: topical administration via a liquid, gel, cream, or as part of a contact lens or selective release membrane; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, intra-operative instillation or suppository form. A method for facilitating the expectoration of sputum for the purpose of detecting cellular abnormalities indicative of lung disease is also disclosed.

INTERNATIONAL SEARCH REPORT

Inte .ional Application No
PCT/US 00/05282

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/70 A61P43/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 99 09998 A (INSPIRE PHARMACEUTICALS) 4 March 1999 (1999-03-04) page 2-3; claim 1; example 1 ---	1,2
X	WO 96 40059 A (UNIV NORTH CAROLINA) 19 December 1996 (1996-12-19)	1,2
A	page 1, line 21,22; claims 1,3,5,6 ---	9,10
X	LAZAROWSKI ET AL: "UDP activates a mucosal-restricted receptor on human nasal epithelial cells that is distinct from the P2Y2 receptor" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 94, no. 6, March 1997 (1997-03), pages 2599-2603, XP000971233 page 2603, left-hand column, paragraph 3 -right-hand column, paragraph 1 ---	1,2,4,5, 8
A	---	9,11
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

15 December 2000

23/01/2001

Name and mailing address of the ISA
European Patent Office, P.O. Box 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Kanbier, D

INTERNATIONAL SEARCH REPORT

Inte. ional Application No
PCT/US 00/05282

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MASON ET AL: "Regulation of transepithelial ion transport and intracellular calcium by extracellular ATP in human normal and cystic fibrosis airway epithelium" BRITISH JOURNAL OF PHARMACOLOGY, vol. 103, no. 3, 1991, pages 1649-1656, XP000924998 the whole document ---	1,2,8
A	WO 98 19685 A (INSPIRE PHARMACEUTICALS INC) 14 May 1998 (1998-05-14) page 2, line 18-21 page 3, line 21,22 page 5-7 page 8, line 12-14 ---	9,12
A	WO 97 05195 A (UNIV NORTH CAROLINA) 13 February 1997 (1997-02-13) page 2, line 15 -page 3, line 23; claims 1-3,11,13,14; example 1 ---	1,2,9,10
A	WO 98 03177 A (INSPIRE PHARMACEUTICALS INC) 29 January 1998 (1998-01-29) page 3, line 3-9; example 1 page 7, line 6-8; claims 1-4 page 7, line 11-13 ---	9-11
		1-4,6

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 1-8 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Likewise, although claims 9-12 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte ional Application No
PCT/US 00/05282

Patent document cited in search report	Publication date	Patent family member(s)			Publication date																		
WO 9909998	A 04-03-1999	AU 9124998 A	BR 9811612 A	CN 1268056 T	EP 1011688 A	US 6143279 A	US 6022527 A	ZA 9807847 A	16-03-1999	08-08-2000	27-09-2000	28-06-2000	07-11-2000	08-02-2000	28-06-1999								
WO 9640059	A 19-12-1996	US 5635160 A	AU 696845 B	AU 6176496 A	BR 9609063 A	CA 2223894 A	EP 0831777 A	JP 11506790 T	NO 975632 A	US 5935555 A	03-06-1997	17-09-1998	30-12-1996	26-01-1999	19-12-1996	01-04-1998	15-06-1999	03-02-1998	10-08-1999				
WO 9819685	A 14-05-1998	AU 4986697 A	BR 9714312 A	CN 1236318 A	EP 0941099 A	NO 992197 A	29-05-1998	02-05-2000	24-11-1999	15-09-1999	05-07-1999												
WO 9705195	A 13-02-1997	US 5628984 A	AU 705528 B	AU 6639996 A	BR 9610059 A	CA 2226892 A	CN 1191553 A	EP 0841900 A	JP 11509759 T	NO 980279 A	US 6133247 A	US 5902567 A	13-05-1997	27-05-1999	26-02-1997	02-03-1999	13-02-1997	26-08-1998	20-05-1998	31-08-1999	21-01-1998	17-10-2000	11-05-1999
WO 9803177	A 29-01-1998	US 5789391 A	AU 4408997 A	CA 2259552 A	CN 1227491 A	EP 0939637 A	US 5958897 A	US 5981506 A	US 5972904 A	04-08-1998	10-02-1998	29-01-1998	01-09-1999	08-09-1999	28-09-1999	09-11-1999	26-10-1999						